Department of Pathology, Roswell Park Cancer Institute, Buffalo, NY, USA.
Gynecol Oncol. 2012 Jan;124(1):148-52. doi: 10.1016/j.ygyno.2011.09.037. Epub 2011 Oct 19.
Synuclein-γ (SNCG) is a marker for adverse and aggressive disease in breast cancer. In previous study, we found SNCG mRNA to be overexpressed in uterine serous carcinoma compared to uterine endometrioid adenocarcinoma. The aim of this study is to explore the prognostic value of SNCG in patients with endometrial cancer.
279 endometrial cancer patients were retrieved from the archives. The tissue paraffin blocks were stained for SNCG antibody and its expression was correlated with clinicopathological prognostic factors.
There was a positive association between SNCG(+) immunoexpression and tumor grade, tumor stage, type II carcinomas, deep myometrial invasion and lymphovascular invasion. A correlation between SNCG(+) and adverse outcomes, such as shorter overall survival (OS) and disease free survival (DFS), was also detected. Following adjuvant therapy (radiation and chemotherapy or chemotherapy alone), we observed a difference in 5years DFS rate between SNCG(+) (41.6%) and SNCG(-) patients (59.5%).
Overexpression of SNCG seemed to be a predictor biomarker for aggressive tumor behavior and adverse outcome in patients with endometrial cancer. Future exploration of SNCG as a potential therapeutic target for selected patients could be of interest.
γ-突触核蛋白（SNCG）是乳腺癌不良侵袭性疾病的标志物。在之前的研究中，我们发现与子宫内膜样腺癌相比，SNCGmRNA 在子宫浆液性癌中过表达。本研究旨在探讨 SNCG 在子宫内膜癌患者中的预后价值。
从档案中检索了 279 例子宫内膜癌患者。对组织石蜡块进行 SNCG 抗体染色，并将其表达与临床病理预后因素相关联。
SNCG（+）免疫表达与肿瘤分级、肿瘤分期、II 型癌、深层肌层浸润和脉管浸润呈正相关。还检测到 SNCG（+）与不良结局之间的相关性，例如总生存期（OS）和无病生存期（DFS）较短。在接受辅助治疗（放疗和化疗或单独化疗）后，我们观察到 SNCG（+）（41.6%）和 SNCG（-）患者（59.5%）之间 5 年 DFS 率存在差异。
SNCG 的过表达似乎是子宫内膜癌患者侵袭性肿瘤行为和不良预后的预测生物标志物。未来探索 SNCG 作为选定患者潜在治疗靶点的可能性可能会引起关注。
